|Podcasts|August 19, 2021

Episode 89: Cellicon Valley Outlook

Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s borders.

Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s borders.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.